Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis

Zhan,Shi‑Jie; Liu,Bin; Linghu,Hua

doi:10.3892/or.2018.6383

Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis

Authors:
- Shi‑Jie Zhan
- Bin Liu
- Hua Linghu
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Pathology, The Basic Medical School of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: April 19, 2018 https://doi.org/10.3892/or.2018.6383
Pages: 2653-2663
Copyright: © Zhan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Serous ovarian cancer (SOC) accounts for >50% of all epithelial ovarian cancers. However, patients with SOC present with various degrees of response to platinum‑based chemotherapy and, thus, their survival may differ. The present study aimed to identify the candidate genes involved in the carcinogenesis and drug resistance of SOC by analyzing the microarray datasets GDS1381 and GDS3592. GDS1381 and GDS3592 were downloaded from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/gds/). A total of 219 differentially expressed genes (DEGs) were identified. Potential genes that may predict the response to carboplatin and, thus, the prognosis of SOC were analyzed. The enriched functions and pathways of DEGs included extracellular region, extracellular space and extracellular exosome, among others. Upon screening the upregulated and downregulated genes on the connectivity map, 10 small‑molecule drugs were identified that may be helpful in improving drug sensitivity in patients with ovarian cancer. A total of 30 hub genes were screened for further analysis after constructing the protein‑to‑protein interaction network. Through survival analysis, comparison of genes across numerous analyses, and immunohistochemistry, GNAI1, non‑structural maintenance of chromosomes (non‑SMC) condensin I complex subunit H (NCAPH), matrix metallopeptidase 9 (MMP9), aurora kinase A (AURKA) and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) were identified as the key molecules that may be involved in the carcinogenesis and carboplatin resistance of SOC. In conclusion, GNAI1, NCAPH, MMP9, AURKA and EZH2 should be examined in further studies for the possibility of their participation in the carcinogenesis and carboplatin response of SOC.

View Figures

View References

1	International Agency for Research on CancerGlobal cancer statistics. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
2	De Las Rivas J and Fontanillo C: Protein-protein interactions essentials: Key concepts to building and analyzing interactome networks. PLoS Comput Biol. 6:e10008072010. View Article : Google Scholar : PubMed/NCBI
3	Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
4	Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
5	Wiggans AJ, Cass GK, Bryant A, Lawrie TA and Morrison J: Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev: CD007929. 2015. View Article : Google Scholar
6	Olopade OI and Wei M: FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 3:417–420. 2003. View Article : Google Scholar : PubMed/NCBI
7	Malati T: Tumour markers: An overview. Indian J Clin Biochem. 22:17–31. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kurman RJ and Shih Ie M: Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 27:151–160. 2008.PubMed/NCBI
9	Lee E and Moon A: Identification of biomarkers for breast cancer using databases. J Cancer Prev. 21:235–242. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
11	Lin CM and Feng W: Microarray and synchronization of neuronal differentiation with pathway changes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) databank in nerve growth factor-treated PC12 cells. Curr Neurovasc Res. 9:222–229. 2012. View Article : Google Scholar : PubMed/NCBI
12	Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C and Jensen LJ: STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41:(Database Issue). D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
13	Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
14	Connectivity Map. https://portals.broadinstitute.org/cmap
15	Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc. 53:457–481. 1958. View Article : Google Scholar
16	Gyorffy B, Lánczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
17	The Human Protein Atlas. https://www.proteinatlas.org/about
18	Protein Atlas version 18. https://www.proteinatlas.org/about/releases
19	GNAI1/pathology/tissue/ovarian+cancer. https://www.proteinatlas.org/ENSG00000127955-GNAI1/pathology/tissue/ovarian+cancer
20	NCAPH/pathology/tissue/ovarian+cancer. https://www.proteinatlas.org/ENSG00000121152-NCAPH/pathology/tissue/ovarian+cancer
21	MMP9/pathology/tissue/ovarian+cancer. https://www.proteinatlas.org/ENSG00000100985-MMP9/pathology/tissue/ovarian+cancer
22	AURKA/pathology/tissue/ovarian+cancer. https://www.proteinatlas.org/ENSG00000087586-AURKA/pathology/tissue/ovarian+cancer
23	EZH2/pathology/tissue/ovarian+cancer. https://www.proteinatlas.org/ENSG00000106462-EZH2/pathology/tissue/ovarian+cancer
24	Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, Dickey BF and Moghaddam SJ: Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res. 4:51–64. 2011. View Article : Google Scholar
25	Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, et al: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 19:456–469. 2011. View Article : Google Scholar : PubMed/NCBI
26	Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, et al: Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS One. 8:e808852013. View Article : Google Scholar : PubMed/NCBI
27	Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T and Ogura T: Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 71:1095–1098. 1995. View Article : Google Scholar : PubMed/NCBI
28	Yeh HH, Lai WW, Chen HH, Liu HS and Su WC: Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 25:4300–4309. 2006. View Article : Google Scholar : PubMed/NCBI
29	Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg JF: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
30	Haura EB, Livingston S and Coppola D: Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer. 7:273–275. 2006. View Article : Google Scholar : PubMed/NCBI
31	Brooks GD, McLeod L, Alhayyani S, Miller A, Russell PA, Ferlin W, Rose-John S, Ruwanpura S and Jenkins BJ: IL6 trans-signaling promotes KRAS-driven lung carcinogenesis. Cancer Res. 76:866–876. 2016. View Article : Google Scholar : PubMed/NCBI
32	GeneSupport Center of NCBI. https://www.ncbi.nlm.nih.gov/gene/
33	Neuwald AF and Hirano T: HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. Genome Res. 10:1445–1452. 2000. View Article : Google Scholar : PubMed/NCBI
34	Wang J, Wu Y, Guo J, Fei X, Yu L and Ma S: Adipocyte-derived exosomes promote lung cancer metastasis by increasing MMP9 activity via transferring MMP3 to lung cancer cells. Oncotarget. 8:81880–81891. 2017.PubMed/NCBI
35	Chen Q, Yin D, Zhang Y, Yu L, Li XD, Zhou ZJ, Zhou SL, Gao DM, Hu J, Jin C, et al: MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. Cell Death Dis. 8:e29062017. View Article : Google Scholar : PubMed/NCBI
36	Xie H, Li L, Zhu G, Dang Q, Ma Z, He D, Chang L, Song W, Chang HC, Krolewski JJ, et al: Correction: Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signals. Oncotarget. 7:83829–83830. 2016. View Article : Google Scholar : PubMed/NCBI
37	Limoge M, Safina A, Beattie A, Kapus L, Truskinovsky AM and Bakin AV: Tumor-fibroblast interactions stimulate tumor vascularization by enhancing cytokine-driven production of MMP9 by tumor cells. Oncotarget. 8:35592–35608. 2017. View Article : Google Scholar : PubMed/NCBI
38	Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, et al: EV-associated MMP9 in high-grade serous ovarian cancer is preferentially localized to Annexin V-Binding EVs. Dis Markers. 2017:96531942017. View Article : Google Scholar : PubMed/NCBI
39	Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et al: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998. View Article : Google Scholar : PubMed/NCBI
40	Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 20:189–193. 1998. View Article : Google Scholar : PubMed/NCBI
41	Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI
42	Bao Z, Lu L, Liu X, Guo B, Zhai Y, Li Y, Wang Y, Xie B, Ren Q, Cao P, et al: Association between the functional polymorphism Ile31Phe in the AURKA gene and susceptibility of hepatocellular carcinoma in chronic hepatitis B virus carriers. Oncotarget. 8:54904–54912. 2017. View Article : Google Scholar : PubMed/NCBI
43	Wang L, Arras J, Katsha A, Hamdan S, Belkhiri A, Ecsedy J and El-Rifai W: Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib. Mol Oncol. 11:981–995. 2017. View Article : Google Scholar : PubMed/NCBI
44	Do TV, Hirst J, Hyter S, Roby KF and Godwin AK: Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget. 8:50376–50392. 2017. View Article : Google Scholar : PubMed/NCBI
45	Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, et al: Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 16:3171–3181. 2010. View Article : Google Scholar : PubMed/NCBI
46	Wang Y, Wang Z, Qi Z, Yin S, Zhang N, Liu Y, Liu M, Meng J, Zang R, Zhang Z and Yang G: The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy. Mol Cancer. 13:942014. View Article : Google Scholar : PubMed/NCBI
47	Brodie KM and Henderson BR: Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: A role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem. 287:7701–7716. 2012. View Article : Google Scholar : PubMed/NCBI
48	Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD II, Lanchbury JS and Krivak TC: BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 125:677–682. 2012. View Article : Google Scholar : PubMed/NCBI
49	Muggia F and Safra T: ‘BRCAness’ and its implications for platinum action in gynecologic cancer. Anticancer Res. 34:551–556. 2014.PubMed/NCBI
50	Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
51	Gao J, Zhu Y, Nilsson M and Sundfeldt K: TGF-β isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int. 14:722014. View Article : Google Scholar : PubMed/NCBI
52	Villanueva MT: Anticancer drugs: All roads lead to EZH2 inhibition. Nat Rev Drug Discov. 16:2392017. View Article : Google Scholar : PubMed/NCBI